Tucatinib interactions

Full monograph for Tucatinib Check it against another medicine

Medicines

369 documented

Severity

Mechanism

Medicines documented to interact with Tucatinib, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Abemaciclib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of abemaciclib and its pharmacologically active…	4 sources — open the full entry
Abiraterone Acetate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 2C8 may increase the plasma concentrations of tucatinib, which is primarily metabolized by the isoenzyme…	1 sources — open the full entry
Acalabrutinib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by…	4 sources — open the full entry
Alfuzosin Hydrochloride	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of alfuzosin, which is primarily metabolized by the…	8 sources — open the full entry
Apalutamide	Major	Metabolism	Coadministration with potent CYP450 3A4 or moderate CYP450 2C8 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by…	2 sources — open the full entry
Apixaban	Major	Absorption · Metabolism	Coadministration with potent inhibitors of CYP450 3A4 that can also inhibit P-glycoprotein (P-gp) may significantly increase the plasma concentrations of…	6 sources — open the full entry
Artemether + Lumefantrine	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized…2 documented mechanisms	9 sources — open the full entry
Avanafil	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avanafil, which is primarily metabolized by the…	10 sources — open the full entry
Axitinib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the…	7 sources — open the full entry
Azelastine Hydrochloride + Fluticasone Propionate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation…	40 sources — open the full entry
Brexpiprazole	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these…	5 sources — open the full entry
Brigatinib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by the…	4 sources — open the full entry
BudesonideInhaler Nebuliser Suspension Tablet	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic bioavailability of budesonide, which undergoes extensive…	19 sources — open the full entry
Budesonide + Formoterol Fumarate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic bioavailability of budesonide, which undergoes extensive…	19 sources — open the full entry
Budesonide + Glycopyrronium Bromide + Formoterol Fumarate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic bioavailability of budesonide, which undergoes extensive…	19 sources — open the full entry
Cabozantinib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. High…	7 sources — open the full entry
Capmatinib Hydrochloride	Major	Metabolism	Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung…	3 sources — open the full entry
Carbamazepine	Major	Metabolism	Coadministration with potent CYP450 3A4 or moderate CYP450 2C8 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by…	2 sources — open the full entry
Cariprazine	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cariprazine and its major active metabolite…	5 sources — open the full entry
Ceritinib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme…	6 sources — open the full entry
Cilostazol	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active…	12 sources — open the full entry
Clopidogrel + Aspirin	Major	Metabolism	Coadministration with potent inhibitors of CYP450 2C8 may increase the plasma concentrations of tucatinib, which is primarily metabolized by the isoenzyme…	1 sources — open the full entry
Clopidogrel Bisulphate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 2C8 may increase the plasma concentrations of tucatinib, which is primarily metabolized by the isoenzyme…	1 sources — open the full entry
Colchicine	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the…	44 sources — open the full entry
Crizotinib	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of crizotinib, which is primarily metabolized by the…	6 sources — open the full entry
Cyclosporine (Oral)	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by…	14 sources — open the full entry
Daclatasvir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by…	4 sources — open the full entry
Daclatasvir + Sofosbuvir	Major	Absorption · Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by…2 documented mechanisms	5 sources — open the full entry
Darifenacin	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by…	7 sources — open the full entry
Dasatinib	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by…	8 sources — open the full entry
Deflazacort	Major	Metabolism	Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active…	3 sources — open the full entry
Docetaxel Trihydrate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma…	21 sources — open the full entry
Drospirenone	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…	9 sources — open the full entry
Drospirenone + Estetrol	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…	9 sources — open the full entry
Drospirenone + Estradiol	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms	10 sources — open the full entry
Drospirenone + Ethinyl Estradiol0.02 mg 0.03 mg	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms	10 sources — open the full entry
Drospirenone + Ethinyl Estradiol + Levomefolate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms	10 sources — open the full entry
Econazole Nitrate + Triamcinolone Acetonide	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of triamcinolone.	14 sources — open the full entry
Elacestrant	Major	Metabolism	Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elacestrant, which is primarily…	1 sources — open the full entry
Enzalutamide	Major	Metabolism	Coadministration with potent CYP450 3A4 or moderate CYP450 2C8 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by…	2 sources — open the full entry
Eplerenone	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which…	3 sources — open the full entry
Ergometrine Maleate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ergot derivatives, which are primarily…	59 sources — open the full entry
ErythromycinLotion Oral	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme…	11 sources — open the full entry
Eszopiclone	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-)…	7 sources — open the full entry
Everolimus	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral…	5 sources — open the full entry
Fentanyl Citrate	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme. Increased…	12 sources — open the full entry
Fesoterodine Fumarate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine…	5 sources — open the full entry
Finerenone	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by…	3 sources — open the full entry
Flibanserin	Major	Metabolism	Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…	2 sources — open the full entry
Fluticasone Furoate	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation…	40 sources — open the full entry

Conditions

Conditions in which Tucatinib needs care, as documented in this source.

Hepatic Insufficiency
Moderate
Tucatinib is an hepatotoxic drug. Additionally, its exposure is increased in patients with severe hepatic impairment, reason why the dosage has to be reduced in these patients (Child-Pugh C). Consult the manufacturers prescribing information for details on dosage modification.
1 source
1. "Product Information. Tukysa (tucatinib)." Seattle Genetics Inc (2020):